According to Glagolev, about 10% of the volunteers had the so-called flu-like syndrome, which is characterized by an increase in body temperature.
“Flu-like syndrome, which occurs in about 10% of those who receive the vaccine, [проявляется] in the form of an increase in temperature, usually no more than 38 degrees, which is removed by non-steroidal anti-inflammatory drugs. In particular, it is well removed with paracetamol. There were no serious undesirable, unforeseen reactions during the clinical trial, ”the Deputy Minister of Health said. He also noted that the vaccine has a “very good safety profile.”
At the moment, about 24 thousand volunteers are participating in post-marketing vaccine studies. Sergey Glagolev promised that the results will be published in one peer-reviewed scientific journal in the very near future.
At the end of November, the developers of the Sputnik V vaccine announced the results of an interim analysis of clinical trials, evaluating the effectiveness of the drug above 95%. On the 28th day after the introduction of the first injection (seven days after receiving the second), the efficiency was 91.4%. 42 days after the first dose and subject to the patients receiving the second dose, the protection level exceeded 95%. It is during this period that a stable immune response is formed, the report says.
The data is based on an analysis of the health status of nearly 19,000 people who received the Sputnik V vaccine during the final clinical trials. Half of the volunteers were injected with the drug, the other half received a placebo. In this sample, 39 cases of confirmed COVID-19 were registered, of which 31 were in the placebo group.